Phase II Study of Temozolomide in Combination with Topotecan (TOTEM) in Relapsed or Refractory Neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma Study
Overview
Authors
Affiliations
Purpose: To assess objective response rate (ORR) after two cycles of temozolomide in combination with topotecan (TOTEM) in children with refractory or relapsed neuroblastoma.
Patients And Methods: This multicenter, non-randomised, phase II study included children with neuroblastoma according to a two-stage Simon design. Eligibility criteria included relapsed or refractory, measurable or metaiodobenzylguanidine (mIBG) evaluable disease, no more than two lines of prior treatment. Temozolomide was administered orally at 150mg/m(2) followed by topotecan at 0.75mg/m(2) intravenously for five consecutive days every 28days. Tumour response was assessed every two cycles according to International Neuroblastoma Response Criteria (INRC), and reviewed independently.
Results: Thirty-eight patients were enroled and treated in 15 European centres with a median age of 5.4years. Partial tumour response after two cycles was observed in 7 out of 38 evaluable patients [ORR 18%, 95% confidence interval (CI) 8-34%]. The best ORR whatever the time of evaluation was 24% (95% CI, 11-40%) with a median response duration of 8.5months. Tumour control rate (complete response (CR)+partial response (PR)+mixed response (MR)+stable disease (SD)) was 68% (95% CI, 63-90%). The 12-months Progression-Free and Overall Survival were 42% and 58% respectively. Among 213 treatment cycles (median 4, range 1-12 per patient) the most common treatment-related toxicities were haematologic. Grade 3/4 neutropenia occurred in 62% of courses in 89% of patients, grade 3/4 thrombocytopenia in 47% of courses in 71% of patients; three patients (8%) had febrile neutropenia.
Conclusion: Temozolomide-Topotecan combination results in very encouraging ORR and tumour control in children with heavily pretreated recurrent and refractory neuroblastoma with favourable toxicity profile.
Moreno L, Weston R, Owens C, Valteau-Couanet D, Gambart M, Castel V J Clin Oncol. 2024; 42(10):1135-1145.
PMID: 38190578 PMC: 11003502. DOI: 10.1200/JCO.23.00458.
De Ioris M, Fabozzi F, Del Bufalo F, Del Baldo G, Villani M, Cefalo M Sci Rep. 2023; 13(1):19295.
PMID: 37935707 PMC: 10630499. DOI: 10.1038/s41598-023-44993-9.
Brignole C, Calarco E, Bensa V, Giusto E, Perri P, Ciampi E J Immunother Cancer. 2023; 11(9).
PMID: 37775116 PMC: 10546160. DOI: 10.1136/jitc-2023-007174.
Olgun N, Cecen E, Ince D, Kizmazoglu D, Baysal B, Onal A Front Oncol. 2023; 12:1041443.
PMID: 36620564 PMC: 9816792. DOI: 10.3389/fonc.2022.1041443.
Jazmati D, Hero B, Thole-Kliesch T, Merta J, Deubzer H, Baumer C Curr Oncol. 2022; 29(11):8222-8234.
PMID: 36354709 PMC: 9689739. DOI: 10.3390/curroncol29110649.